SHARE THIS ARTICLE
Hymovis
Hymovis vs Euflexxa – Which is Better for OA?
Nov 20, 2024
Osteoarthritis (OA) is a common joint disorder affecting millions worldwide. According to a comprehensive review, OA is the most prevalent form of arthritis in the United States, impacting 22.7% of the adult population. The knee is the most commonly affected joint, with up to 41% of OA cases involving this area.
Two popular treatments for knee OA are Hymovis and Euflexxa. Both are hyaluronic acid injections designed to alleviate pain and improve joint function. Hymovis and Euflexxa have shown varying degrees of effectiveness in clinical studies, making it important to compare their benefits and drawbacks.
In this article, we will compare Hymovis vs Euflexxa, examining their effectiveness, treatment regimens, and potential side effects to determine which may be more suitable for managing osteoarthritis symptoms.
Key Takeaways
- Hymovis uses a thicker, highly viscoelastic hyaluronic acid requiring just two injections, while Euflexxa mimics natural joint fluid in a three-injection series.
- Both treatments effectively improve knee mobility and reduce osteoarthritis pain, with Hymovis offering results lasting up to a year and Euflexxa lasting around six months.
- Both are FDA-approved and have established safety profiles. They have mild side effects, such as swelling or discomfort at the injection site.
- Hymovis is preferred for convenience, while Euflexxa appeals to those who favor a gradual improvement through a traditional schedule.
About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Hymovis online, contact our sales team for guidance.
Understanding Hymovis and Euflexxa
Hymovis and Euflexxa are injectable viscosupplements designed to relieve knee pain caused by osteoarthritis. They differ in formulation, mechanism of action, and treatment schedules. Hymovis features a unique, highly viscoelastic hyaluronic acid that provides prolonged joint lubrication and cushioning. Its thicker consistency requires only two injections, spaced one week apart, making it a convenient option for patients.
On the other hand, Euflexxa mimics the natural viscosity of synovial fluid to improve joint function. Administered as a series of three weekly injections, it gradually enhances lubrication and reduces friction in the knee joint. Both treatments aim to restore joint mobility and alleviate pain by replenishing hyaluronic acid levels depleted by osteoarthritis.
While Hymovis offers faster completion of treatment, Euflexxa’s gradual approach suits patients who may prefer a more traditional regimen. Both options are FDA-approved, providing safe and effective relief for individuals who have not found success with conventional therapies.
Efficacy Comparison
When it comes to pain relief and joint lubrication, both Hymovis and Euflexxa have shown promising results in clinical studies. Hymovis has been found to significantly improve knee function and reduce pain in patients with osteoarthritis. A study showed that patients experienced improved knee function and reduced pain for up to 360 days after a single injection.
Euflexxa has also demonstrated robust pain relief in multiple clinical trials. A 12-week study found it to be non-inferior to Synvisc, another popular viscosupplement, in reducing pain. In another trial, Euflexxa also provided significant pain relief for up to 26 weeks.
In terms of the duration of results, both treatments offer extended relief, but the exact duration can vary among patients. Hymovis has shown lasting effects for up to a year in some patients, while Euflexxa has been effective for up to six months. The overall effectiveness of both treatments is comparable, with both providing meaningful improvements in pain and joint function
Safety Profiles and Patient Satisfaction
Hymovis and Euflexxa have established safety profiles and are FDA-approved for treating knee osteoarthritis. Hymovis FDA approval ensures its use as a reliable viscosupplement with minimal risk of adverse effects.
Common side effects for both treatments include mild pain, swelling, or stiffness at the injection site, which typically resolve within a few days. Serious complications, such as infections or allergic reactions, are extremely rare when administered by a qualified professional.
Patient satisfaction with both treatments is generally high, with many reporting significant reductions in pain and improved mobility. Hymovis’s two-injection regimen is especially appreciated for its convenience, while Euflexxa’s gradual three-injection protocol appeals to those who prefer a slower, steady improvement.
On Hymovis
- biz…: “I love it! I was getting another injection every six months. Hymovis has been working very well for me. Now I get Hymovis every 12 months.”
On Euflexxa
- San…: “Started Euflexxa over 5 years ago for bone-on-bone in both knees. I have a series of three weekly injections twice a year. I walk every day and do Zumba twice a week. I have absolutely no pain with the injections (my doctor knows what he is doing) and have been relatively pain-free. I am a 73-year-old female.”
Choosing the Right Treatment for OA
Choosing the right treatment for knee osteoarthritis (OA) requires a thoughtful approach that considers the patient’s needs and the unique features of each therapy. Practitioners are crucial in guiding this decision by evaluating factors like treatment goals, lifestyle preferences, and medical history.
Hymovis is ideal for patients seeking a convenient two-injection regimen with a thicker hyaluronic acid formulation for extended relief. In contrast, Euflexxa offers a three-injection schedule that mimics the natural viscosity of the joint fluid, providing a steady improvement over time. For patients who prioritize fewer visits, Hymovis may be more suitable, while those who prefer gradual symptom relief might opt for Euflexxa.
Additional considerations include each treatment’s duration of effectiveness. Practitioners can ensure optimal outcomes and satisfaction by aligning treatment choices with the patient’s goals—whether for pain relief, improved mobility, or both.
Conclusion
Hymovis and Euflexxa represent two excellent options for managing knee osteoarthritis through viscosupplementation. Hymovis stands out for its convenient two-injection regimen and longer-lasting effects, making it ideal for patients seeking fewer visits and extended relief. Euflexxa, with its three-injection protocol, offers a gradual but steady improvement in joint function and pain relief, mimicking the natural viscosity of joint fluid.
Both treatments have proven their effectiveness and safety in clinical studies. The choice largely depends on individual preferences, treatment goals, and lifestyle needs. Consulting with a healthcare provider is key to selecting the best option for managing osteoarthritis.
FAQs
1. How long does relief from Hymovis last?
Hymovis has been shown to relieve pain and improve joint function for up to one year in some patients.
2. Who is a good candidate for Hymovis?
Hymovis is ideal for patients with knee osteoarthritis who have not found relief from other conservative treatments like physical therapy or oral pain medications.
3. How does Hymovis compare to Euflexxa?
Hymovis offers a two-injection regimen with longer-lasting results, while Euflexxa requires three injections and provides steady, gradual relief. Both are effective but cater to different patient preferences.
References
Peck J, Slovek A, Miro P, et al. A comprehensive review of viscosupplementation in osteoarthritis of the knee. Orthopedic Reviews. 2021;13(2). doi:10.52965/001c.25549
Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee Osteoarthritis. Ichgcp.net. Published May 8, 2024. Accessed November 20, 2024. https://ichgcp.net/clinical-trials-registry/NCT06528600